BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
Rhea-AI Summary
BioCardia (NASDAQ:BCDA) will host a Q1 2026 financial results and corporate update conference call on May 15, 2026 at 4:30 PM EDT. The event includes management remarks and a Q&A session, with access via phone registration or live webcast and replay options.
Positive
- None.
Negative
- None.
News Market Reaction – BCDA
In the May 12 session, BCDA gained 0.90%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-03-19 | Earnings call notice | Neutral | +0.0% | Announcement of 2025 results call and corporate update schedule. |
| 2025-11-05 | Quarterly call notice | Neutral | -3.0% | Scheduling Q3 2025 update and results conference call. |
| 2025-08-06 | Quarterly call notice | Neutral | -5.5% | Scheduling Q2 2025 earnings and corporate update call. |
| 2025-05-09 | Quarterly call notice | Neutral | -0.3% | Scheduling Q1 2025 update and financial results call. |
| 2025-03-21 | Full-year call notice | Neutral | +7.7% | Scheduling 2024 results release and corporate update call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference/earnings call announcements have historically led to modest, mixed price reactions, with a slight negative average move.
Over the past five conference/earnings-tagged events, BioCardia has repeatedly announced scheduled financial results calls and corporate updates, typically at 4:30 PM EDT with webcast and replay access. Price reactions around these announcements have ranged from a -5.52% decline to a 7.69% gain, averaging about -0.24%. This Q1 2026 call notice fits a consistent pattern of routine communication rather than a new clinical or regulatory catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, May 15, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to: https://dpregister.com/sreg/10209272/104069d5d88.
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Rt7kKGAp.
A webcast replay of the call will be available approximately one hour after the end of the call through approximately August 15, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 4737992.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information visit www.biocardia.com.
MEDIA CONTACT: Miranda Peto, Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120